Cryoport Systems Expands IntegriCell™ Cryopreservation Services with European Center of Excellence in Belgium

At Cryoport Systems, we are committed to advancing cell therapy supply chain management, ensuring that our clients can deliver life-saving treatments to patients around the world. We are excited to announce the opening of our new IntegriCell™ Center of Excellence in Villers-le-Bouillet, Belgium, marking an expansion of our global cryopreservation capabilities and reinforcing our dedication to innovation in the cell therapy supply chain. 

This new, custom-built 13,401 square-foot facility is fully GMP-compliant and purpose-designed for the cryopreservation of leukapheresis starting materials, which are critical for a variety of cell-based therapies. With an annual capacity to cryopreserve up to 1,100 leukapheresis products, this facility provides a valuable, reliable resource for clients who need consistent, high-quality cryopreserved materials for their clinical and commercial cell therapy programs. 

IntegriCell™: A Holistic Cryopreservation Solution 

IntegriCell™ cryopreservation by Cryoport Systems is more than just a cryopreservation service; it is a comprehensive solution tailored to meet the evolving needs of the global cell therapy market. IntegriCell™ combines standardized bioprocessing and cryopreservation with advanced logistics and distribution services, providing clients with a seamless and reliable solution for maintaining the viability and quality of critical cellular materials. This solution helps address a pressing need in the industry: ensuring the stability and integrity of cell therapies as they move from research and development to commercialization. 

By expanding our IntegriCell™ capabilities into Europe with the new Belgium facility, we are not only enhancing local access for clients but also establishing an interconnected network of facilities that can consistently deliver high-quality, manufacture-ready cryopreserved leukopaks. As a Center of Excellence, the Belgium site will also serve as a resource for sharing optimized preservation processes across facilities worldwide, reinforcing consistency for global cell therapy programs. 

Supporting the Advancement of Cell-Based Therapies 

Cryopreservation is a foundational aspect of cell therapy logistics. For therapies that rely on cellular starting materials such as leukapheresis, ensuring that these materials remain viable from collection to administration is crucial. IntegriCell™, now with expanded capabilities in Belgium, offers an enhanced level of control, flexibility, and reliability to support this process. As the industry continues to grow and more therapies reach commercialization, IntegriCell™ provides the standardization and scalability necessary to meet patient needs efficiently. 

Expanding Global Support for a Growing Market 

The opening of the Belgium Center of Excellence aligns with our broader mission to provide world-class support to our clients at every stage of their therapeutic development journey. By expanding our IntegriCell™ platform to Europe, we’re offering clients in the region faster, more efficient access to critical cryopreservation resources. The new site not only increases capacity but also enables Cryoport Systems to streamline the cryopreservation process, from cryopreservation to global distribution. 

The new IntegriCell™ facility in Belgium represents a major milestone for Cryoport Systems and the cell therapy community. This expansion provides a robust foundation to support the continued growth of cell-based therapies and ensures that these treatments are accessible to patients in Europe and beyond.